ResearcherJohns Hopkins UniversityActive in the last 2 years
Elie M. Ghabi
Matched on ORCID iD 0000-0002-9026-9681; OpenAlex author ID A5063320941. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 27
2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity. Co-author DOI 10.1158/0008-5472.can-25-3126↗
- Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05476-w↗
- Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
Closest collaborators
The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jin Peng He · 3 shared papers, 2023–2026 · strength 0.50
- Paper KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity. DOI 10.1158/0008-5472.can-25-3126↗
- Paper Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pan… DOI 10.1007/s11605-022-05476-w↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Christopher R. Shubert · 2 shared papers, 2023 · strength 0.30
- Paper Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pan… DOI 10.1007/s11605-022-05476-w↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- William R. Burns · 2 shared papers, 2023 · strength 0.30
- Paper Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pan… DOI 10.1007/s11605-022-05476-w↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Sami Shoucair · 2 shared papers, 2023 · strength 0.30
- Paper Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pan… DOI 10.1007/s11605-022-05476-w↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Kelly J. Lafaro · 2 shared papers, 2023 · strength 0.30
- Paper Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pan… DOI 10.1007/s11605-022-05476-w↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Richard Andrew Burkhart · 2 shared papers, 2023 · strength 0.30
- Paper Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pan… DOI 10.1007/s11605-022-05476-w↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Christopher L. Wolfgang · 2 shared papers, 2023 · strength 0.30
- Paper Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pan… DOI 10.1007/s11605-022-05476-w↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Lei Zheng · 2 shared papers, 2023 · strength 0.30
- Paper Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pan… DOI 10.1007/s11605-022-05476-w↗
- Paper Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therap… DOI 10.1097/js9.0000000000000200↗
- Audrey M. Hendley · 1 shared paper, 2026 · strength 0.20
- Giuseppe Malleo · 1 shared paper, 2026 · strength 0.20
- Rondell Patrell Graham · 1 shared paper, 2026 · strength 0.20
- Grace Kim · 1 shared paper, 2026 · strength 0.20
- Laura Leonhardt · 1 shared paper, 2026 · strength 0.20
- Matthias Hebrok · 1 shared paper, 2026 · strength 0.20
- Claudio Luchini · 1 shared paper, 2026 · strength 0.20
- David W. Dawson · 1 shared paper, 2026 · strength 0.20
- Ding Ding · 1 shared paper, 2023 · strength 0.16
- Ammar A. Javed · 1 shared paper, 2023 · strength 0.16
- Quan Liao · 1 shared paper, 2023 · strength 0.14
- Ming Cui · 1 shared paper, 2023 · strength 0.14
- Junke Wang · 1 shared paper, 2023 · strength 0.14
- Eun Ji Shin · 1 shared paper, 2023 · strength 0.14
- Jun Yu · 1 shared paper, 2023 · strength 0.14
- Joseph R. Habib · 1 shared paper, 2023 · strength 0.14
- Benedict Kinny‐Köster · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.